Current Report Filing (8-k)
October 17 2016 - 9:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The
Securities
Exchange Act of 1934
Date of Report
(Date of earliest event reported): October 17, 2016
CELGENE
CORPORATION
(Exact name of registrant as specified in
its charter)
Delaware
|
001-34912
|
22-2711928
|
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
86 Morris Avenue, Summit, New Jersey
|
|
07901
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (908) 673-9000
(Former name
or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 8.01 OTHER
EVENTS
On October 17,
2016, Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, issued a press release providing additional
data on the ongoing phase 1b CD-001 study exploring the effects of oral GED-0301 (mongersen) on both endoscopic and clinical outcomes
in patients with active Crohn’s disease. Attached hereto and incorporated herein by reference as Exhibit 99.1 is the press
release announcement.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit 99.1 – Press Release dated
October 17, 2016
SIGNATURES
Pursuant to the requirements of the Securities and Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CELGENE CORPORATION
|
|
|
|
Date: October 17, 2016
|
By:
|
/s/ Peter N. Kellogg
|
|
|
|
Peter N. Kellogg
|
|
|
Executive Vice President and
|
|
|
Chief Financial Officer
|
|
|
(principal financial and accounting officer)
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release dated October 17, 2016
|
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Sep 2023 to Sep 2024